Clinical Efficacy of Pravastatin in Patients with Hypercholesterolemia.
10.4070/kcj.1992.22.1.113
- Author:
June Soo KIM
;
Ki Hoon HAN
;
Seung Woo PARK
;
Joon Kyung BANG
;
Suk Keun HONG
;
Dae Won SOHN
;
Byung Hee OH
;
Myoung Mook LEE
;
Young Bae PARK
;
Yun Shik CHOI
;
Jung Don SEO
;
Young Woo LEE
- Publication Type:Original Article
- Keywords:
Hypercholesterolemia;
Pravastatin
- MeSH:
Humans;
Hypercholesterolemia*;
Male;
Oxidoreductases;
Pravastatin*
- From:Korean Circulation Journal
1992;22(1):113-120
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: This study was designed to evaluate the clinical efficacy of pravastatin, HMG-CoA reductase inhibitor, in patients with hypercholesterolemia. Methods and RESULTS: Pravastatin 5 mg was administered twice daily for 12 weeks in twenty five patients(12 male, 13 female) with hypercholesterolemia(>240 mg/dl). Compared with pretreatment levels, pravastatin significantly decreased levels of total cholesterol(281+/-41mg/dl versus 218+/-31mg/dl) by 22% and LDL-cholesterol(199+/-46mg/dl versus 137+/-37mg/dl) by 31% with significantly decreased total-cholesterol/HDL-cholesterol ratio(7.1+/-3.0 versus 5.1+/-1.6) and LDL-cholesterol/HDL-cholesterol ratio(5.1+/-2.5 versus 3.3+/-1.4) (p<0.005, respectively). During pravastatin treatment, the level of Apo B(164+/-38mg/dl versus 123+/-20mg/dl) was decreased significantly by 24% with significantly decreased Apo B/Apo A-1 ratio(1.4+/-0.5 versus 1.0+/-0.3) (p<0.005, respectively). No serious side effects were found. CONCLUSIONS: Results from the present study show that pravastatin is an effective and well-tolerated cholesterol-lowering agent.
